Catalyst Event
Innovent Biologics Inc (1801) · Earnings Release
From Akros SCHK HK-US Biotech Index (ASHUBIO)
3/26/2026, 12:00:00 AM
Innovent Biologics announced its 2025 annual results, reporting total revenue of RMB 13.04 billion, a 38.4% YoY increase. The company achieved its first full-year net profit of RMB 814 million, a significant turnaround from a net loss in 2024. The stock surged over 7% following the announcement.
Korean Translation
2025년 연간 실적 발표, 총 매출 130.4억 위안으로 전년 대비 38.4% 증가함. 사상 최초로 8.14억 위안의 연간 순이익을 달성하며 흑자 전환함. 발표 후 주가 7% 이상 급등함.
Related Recent Events
CSPC Pharmaceutical Group Ltd (1093) · Other
Final dividend of HKD 0.15 per share for FY2025 (total HKD 0.29, +11.5% YoY) with ex-dividend date June 24, 2026; low importance as dividend increases typically result in minor positive price adjustments scheduled.
6/24/2026, 12:00:00 AM
Pfizer Inc (PFE) · Earnings Release
High importance is estimated due to the potential for significant price volatility for Pfizer's Q1 2026 earnings release and conference call, scheduled.
5/5/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Earnings Release
Q1 2026 earnings release and conference call scheduled; typically results in moderate price movement.
4/30/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Earnings Release
Q1 2026 earnings release and conference call scheduled.
4/30/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Earnings Release
Q1 2026 earnings release and conference call for 2026-04-30, estimated to have a low impact of ~1-2% based on historical trends, scheduled.
4/30/2026, 12:00:00 AM
Regeneron Pharmaceuticals Inc (REGN) · Earnings Release
Regeneron is scheduled to report its first quarter 2026 financial and operating results on 2026-04-29. Importance is Medium as earnings typically drive significant price movement, scheduled.
4/29/2026, 12:00:00 AM